Elevance: 3 Key Takeaways for Long-Term Investors
Key Points
Elevance raised its 2026 earnings baseline to at least $26.75 per share.
Carelon's cancer program reduced avoidable inpatient admissions by 15%.
Operating revenue rose by under 1% to $50.4 billion.
- 10 stocks we like better than Elevance Health ›
On its third-quarter 2026 earnings call, held on Oct. 21, 2026, Elevance (NYSE:ELV) announced an increased 2026 earnings baseline of at least $26.75 per share. Long-term investors gain higher visibility into future earnings as Medicaid rates align with medical costs and health services expand. Three things management said stand out.
1. Higher Baseline Guidance Signals Core Earnings Growth
Raising the underlying earnings baseline provides a higher launching pad for future growth. Favorable claims experienced in Individual ACA (Affordable Care Act) health plans supported this higher floor.
Our earnings baseline increases by $0.75 to at least $26.75, reflecting third quarter operating outperformance and an improved full year outlook for Individual ACA.
-- Mark Kaye, Chief Financial Officer
2. Targeted Clinical Programs Cut Hospital Admissions
Elevance relies on clinical management tools inside Carelon, its healthcare services unit, to lower overall medical costs. Coordinating cancer care early keeps patients out of the hospital and reduces expensive claims.
Through earlier identification of risks and more coordinated intervention, our cancer care engagement program has reduced avoidable inpatient admissions by 15% in the commercial market.
-- Gail Boudreaux, President and Chief Executive Officer
3. Combined Pharmacy and Medical Coverage Lowers Customer Costs
Integrating pharmacy benefits with medical coverage creates tangible savings for employer groups. Lower total care expenses help Elevance win and retain large commercial accounts.
What we have seen is, as we integrate medical and pharmacy, our members are benefiting by saving up to $100 per member per month.
-- Mark Kaye, Chief Financial Officer
Looking Ahead
Medical cost trends remain stable across Medicaid and commercial lines, while rate updates support ongoing margin expansion. Elevance leverages its scale across health plans and digital platforms to improve pricing discipline and medical cost control.
As we extend these solutions across our health plans and to external clients, we expect to improve medical cost management, increase operating leverage, and deliver greater value for those we serve.
-- Gail Boudreaux, President and Chief Executive Officer
Management expects broad-based operating improvement to carry momentum into future periods across its entire health benefits portfolio.
Beyond 2027, we believe the actions we are taking today position us to drive sustainable long-term earnings growth.
-- Gail Boudreaux, President and Chief Executive Officer
Should you buy stock in Elevance Health right now?
Before you buy stock in Elevance Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Elevance Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $370,440!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,330,110!*
Now, it’s worth noting Stock Advisor’s total average return is 924% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of October 21, 2026.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
